Canada markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
76.19+0.23 (+0.30%)
At close: 04:00PM EDT
76.43 +0.24 (+0.31%)
After hours: 07:55PM EDT
Sign in to post a message.
  • B
    Berlin 68
    $SLS conversation
    Possible reasons for trading activity
    $ABBV buys SLS, $MRK Buys SLS, $BMY BUYS SLS, IDMC Halts the Phase 3 for Efficacy, FDA AML Approval
  • R
    Real Immuno Investor 10
    $SLS conversation
    MSK Co-Director of Mesothelioma Dept Running the $BMY Opdivo GPS combination trial
    "Median overall survival was 35.4 weeks, the time at which the data was taken. Stergiou expects the median overall survival to be considerably longer when the next report is delivered... By comparison, patients with relapsed or refractory mesothelioma have an estimated median overall survival between 20 and 24 weeks. "

    > NCT Site updated in DEC - should have 10 Patients Mesothelioma is a real MnF'r, any meaningful improvement in Overall Survival will be Major news in the community.

    Ps Dr Zauderer is the Chairperson of the Mesothelioma Hope Organization
    CONSIDERABLY LONGER
    https://www.mskcc.org/cancer-care/clinical-trials/17-654
    \
    Again NKTX added $600M in Market cap based on their Phase 1, 5 patient cohort - due to the nature of the patients - end stage.
  • C
    Cured
    $SLS conversation
    Memorial Sloan Kettering Mesothelioma Co-Director running the $BMY Opdivo GPS combination trial
    > NCT Site updated in DEC - should have a large Patient set. Mesothelioma is a real MnF'r, any meaningful improvement in Overall Survival will be Major news in the community.
    Ps Dr Zauderer is the Chairperson of the Mesothelioma Hope Organization
    "CONSIDERABLY LONGER"
    https://www.mskcc.org/cancer-care/clinical-trials/17-654

    "Median overall survival was 35.4 weeks, the time at which the data was taken. Stergiou expects the median overall survival to be considerably longer when the next report is delivered...

    By comparison, patients with relapsed or refractory mesothelioma have an estimated median overall survival between 20 and 24 weeks. "
    \
    Again NKTX added $600M in Market cap based on their Phase 1, 5 patient cohort - due to the nature of the patients - end stage, exhausted all other options.
  • C
    Cured
    $SLS conversation
    $BMY Gps Opdivo End stage Meso last update:
    “Median OS was 35.4 weeks, the time at which the data was taken. Stergiou expects the median overall survival to be considerably longer when the next report is delivered..patients with relapsed or refractory mesothelioma have a median OS of 22 weeks."
  • R
    Real Immuno Investor 10
    $SLS conversation
    MSK Co-Director of Mesothelioma Dept Running the $BMY Opdivo GPS combination trial
    > NCT Site updated in DEC - should have 10 Patients Mesothelioma is a real MnF'r, any meaningful improvement in Overall Survival will be Major news in the community.
    Ps Dr Zauderer is the Chairperson of the Mesothelioma Hope Organization
    CONSIDERABLY LONGER
    https://www.mskcc.org/cancer-care/clinical-trials/17-654

    "Median overall survival was 35.4 weeks, the time at which the data was taken. Stergiou expects the median overall survival to be considerably longer when the next report is delivered...

    By comparison, patients with relapsed or refractory mesothelioma have an estimated median overall survival between 20 and 24 weeks. "
    \
    Again NKTX added $600M in Market cap based on their Phase 1, 5 patient cohort - due to the nature of the patients - end stage.
  • C
    Cured
    $SLS conversation
    Last june SlS traded up to $15 ahead of small adhoc readouts. Now we will see larger, mature results - Gps is worth billions and Big Pharma will be Paying up Bigly. $MRK or $BMY May decide its time to Guppy this baby BIO
    Merck has zero agents for PROC, Keytruda is ineffective as a single agent - they need Gps.
  • R
    Real Immuno Investor 10
    $SLS conversation
    SLS is worth a Billion Now trades for $50M $bmy $mrk In June Gps Keytruda Ovarian Cancer last update "Median overall survival among the patients in this trial is not yet known as all patients are still alive at the time of the analysis, which period of time exceeds nine months.
    Gps Opdivo End stage Meso last update:
    “Median OS was 35.4 weeks, the time at which the data was taken. Stergiou expects the median overall survival to be considerably longer when the next report is delivered
    ..patients with relapsed or refractory mesothelioma have a median OS of 22
  • J
    Joe
    $SLS conversation
    Last year, this time SlS traded up to $15 ahead of small adhoc readouts. Now we will see larger, mature results - Gps is worth billions and Big Pharma will be Paying up Bigly. $MRK or $BMY May decide its time to Guppy this baby BIO
    Merck has zero agents for PROC, Keytruda is ineffective as a single agent - they need Gps.
  • M
    Mark
    Bmy stock looks like it's about topped out here if we get to about 79. Guidance that was reiterated stops the eps until next year or further developments. Does anyone here see any near term catalyst to make them go higher or is this about dead money for awhile?????
  • R
    Real Immuno Investor 10
    $SLS conversation
    PT $40 $50 "...by the End of Q2" SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely
  • R
    Real Immuno Investor 10
    $SLS conversation
    PT $40 $50 "...by the End of Q2" SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely
  • R
    Real Immuno Investor 10
    $SLS conversation
    PT $40 $50 "...by the End of Q2" SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely

    20M shares x $40 $800M Mc for an effective safe therapy that works for end stage, dying mesothelioma and ovarian cancer patients who have exhausted all treatment options.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Last year, this time SlS traded up to $15 ahead of small adhoc readouts. Now we will see larger, mature results - Gps is worth billions and Big Pharma will be Paying up Bigly. $MRK or $BMY May decide its time to Guppy this baby BIO
    Merck has zero agents for PROC, Keytruda is ineffective as a single agent - they need Gps.
  • V
    VOLPONI
    Just saw BMY published on the daily alert watchlist at (http://market-engross.club)
  • C
    Cured
    $SLS conversation
    In a small $nktx P1 trial 2/5 of 2 mrd- patients added $600 M in shareholder value. Patients who had no other treatment options - same as the $bmy Gps mesothelioma P1 combination patients and the $mrk Keytruda P2 Ovarian Cancer patients for that matter.

    — merck and SlS locked the data and are now conducting Joint analysis to be announced in Q2

    Galinpepimut-S (GPS) in combination with pembrolizumab (Keytruda) shows promising antitumor activity and initial immunobiological activity for Wilms Tumor–1 (WT1)–positive ovarian cancer as part of a phase 1/2 clinical trial, according to a press release from SELLAS Life Sciences Group, Inc.1

    Recent data from the study show 100% of patients in this group (n = 11) are still alive and 5 patients (45.5%) are continuing investigational treatment.

    The open-label, multicenter, multi-arm study has a target enrollment goal of 20 patients with relapsed or refractory, platinum-resistant, advanced ovarian cancer. The primary end points are safety and overall response rate, with secondary end points of progression-free survival (PFS) and overall survival (OS).

    Patients in this study who had previously failed second- or third-line therapy comprised 66.7% and 33.3%, respectively. Although OS data are not mature, all patients remained alive at 9 months which compares favorably with historical OS of 9* months with the standard of care.
  • R
    Real Immuno Investor 10
    $SLS conversation
    By the End of Q2 $bmy $Mrk - Gps Nivolumab Meso sarcomotoid patient with a life expectancy of 6-8 weeks, alive 25 months, at least
    - First Dosed GPS Pembro patient w a LE of 9/10 months survived 24 months at least
    - Gps Moffitt Center Phase 2 AML Cr2 patients survived 21 months vs 5/6 months in the the control
    - Gps Memorial Sloan Kettering Phase 2 AmL cr1 patients median os 67 months vs 26 with OAz (New treatment)
    - GPS Pembro 100% patient survival for as long as the best standard of care median average Survival, trial Results announced in June are 100% guaranteed to better much better than existing best treatment.
    - Dr. Levy Director of Hematologic Research at Baylor University Med has said its virtually certain Gps is working as intended.
    - Investigators who see GPS patients in clinic Requesting Expanded Access to Gps

    IDMC is adding all the evidence, are reviewing to Halt for Efficacy
  • R
    Real Immuno Investor 10
    $SLS conversation
    100% guaranteed the next data sets, must, they can only show vastly superior survival rates over the best treatments. For the Meso trial, as an example, the last data GPS Opdivio patients had a 9 month median OS, (vs 6 with bat) and the CEO said, 'the median os has not been reached yet --> it can only be better, ie it is 100% guaranteed'.
    Do you understand?
    The whole market is going to wake to this fact: GPs + Opdivo is the real deal. $BMY will want to pay big money.
  • J
    Joe
    $SLS conversation
    Last year, about this time SlS traded up to $15 ahead of small adhoc readouts. Now we will see larger, mature results - Gps is worth billions and Big Pharma will be Paying up Bigly. $MRK or $BMY May decide its time to Guppy this baby BIO
    Merck has zero agents for PROC, Keytruda is ineffective as a single agent - they need Gps.

    I keep asking, if merck hasn't already bought SLS does that mean they won't ever?
    ; )
  • G
    Gorgan
    if this was the place to be because of inflation/healthcare, wouldn't we want to see guidance increase?
  • R
    Real Immuno Investor 10
    $SLS conversation
    Next month WE All will wish we Bought more Right now PT $40 $50 "...by the end of Q2"
    SLS has 2 Billion dollar TRIAL hits like what added $.5B to $NKTX
    - Gps Opdivo $BMY Meso patient with a life expectancy of 6-8 weeks, alive 25 months at least
    - 1st Dosed GPS Keytruda $MRK patient w a LE of 9/10 months alive 24 months, so far
    - Moffitt Center GPs P2 AML Secondary remission O Survival 21 months vs 5/6 months in the control patients
    - Sloan Kettering Gps Phase 2 AmL Cr1 patients median OS of 67 months vs 26 with O Az Soc
    - GPS +Pembro 100% patient survival already for as long as the best standard of care average Survival,
    Coming Results in June are 100% guaranteed to better, much better than existing best treatment
    - Dr. Levy Director of Hematologic Research at Baylor Med said its virtually certain Gps P3 will be FDA approved
    - Investigators who see actual GPS P3 patients in clinic Requesting Expanded Access confirms GPS is GOLDEN
    - IDMC now analyzing data for a Possible Halt for Efficacy

    Literally 2,500% ROI is more than likely